Skip to main content
SpringerLink
Log in

Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies

  • Letter to the Editor
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 02 June 2017

The Original Article was published on 28 July 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Notes

  1. Values obtained by subtracting the values of AUCres in Table 3 of Algorta et al. from 100%.

References

  1. Tashkin DP, Bateman ED, Jones P, Zubek VB, Metzdorf N, Liu D, et al. Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: novel and conventional responder analyses. Respir Med. 2016;120:91–100. doi:10.1016/j.rmed.2016.10.002.

    Article  PubMed  Google Scholar 

  2. MHRA-UK. Public Assessment Report (PAR). Braltus 10 microgram per delivered dose inhalation powder, hard capsule; Gregal 10 microgram per delivered dose inhalation powder, hard capsule (tiotropium bromide). 2016. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con723050.pdf. Accessed 19 May 2017.

  3. Algorta J, Andrade L, Medina M, Kirkov V, Arsova S, Li F, et al. Pharmacokinetic bioequivalence of two inhaled tiotropium bromide formulations in healthy volunteers. Clin Drug Invest. 2016;36(9):753–62. doi:10.1007/s40261-016-0441-8.

    Article  CAS  Google Scholar 

  4. EMA-CHMP. Guideline on the investigation of bioequivalence. Doc Ref.: CPMP/EWP/QWP/1401/98Rev.1/Corr. January 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. Accessed 19 May 2017.

  5. EMA-CHMP. Questions and answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP). The extent to which plasma levels reflect bioavailability in the lung. Section 17 part 1, p. 44. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002963.pdf. Accessed 19 May 2017.

  6. EMC-UK. Summary of product characteristics: Spiriva 18 microgram inhalation powder, hard capsule. 2015. Available from: http://www.medicines.org.uk/emc/medicine/10039. Accessed 19 May 2017.

  7. Weber B, Troconiz IF, Borghardt JM, Staab A, Sharma A. Model-based evaluation of single and multiple dose pharmacokinetics of inhaled tiotropium in healthy volunteers and implications for systemic exposure studies. Respir Drug Deliv Eur. 2015;2:249–54.

    Google Scholar 

  8. Sharma A, Weber B, Wein M, Hallmann C, Meibohm B. Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products. Clin Pharmacol Drug Dev. 2016;5(1):52–6. doi:10.1002/cpdd.187.

    Article  CAS  PubMed  Google Scholar 

  9. Weber B, Borghardt JM, Parra-Guillen ZP, Sharma A, Retlich S, Staab A et al. Tiotropium pharmacokinetics and pharmacodynamics: what are drivers for systemic levels and local pulmonary responses? Respir Drug Deliv. 2016;1:45–54.

    Google Scholar 

  10. Price D, Sharma A, Cerasoli F. Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. Expert Opin Drug Metab Toxicol. 2009;5(4):417–24. doi:10.1517/17425250902828337.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the medical writing support of Dr. Paul Tanswell.

Author information

Author notes

  1. Ashish Sharma and Benjamin Weber contributed equally to this article.

Authors and Affiliations

  1. Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, Biberach an der Riss, 88397, Germany

    Ashish Sharma

  2. Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 06877, USA

    Benjamin Weber

  3. College of Pharmacy, University of Tennessee, Memphis, USA

    Bernd Meibohm

Authors
  1. Ashish Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernd Meibohm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashish Sharma.

Ethics declarations

Funding

This study was funded by Boehringer Ingelheim.

Conflict of interest

Ashish Sharma and Benjamin Weber are employees of Boehringer Ingelheim Pharmaceuticals. Bernd Meibohm has consulted for Boehringer Ingelheim Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Weber, B. & Meibohm, B. Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies. Clin Drug Investig 37, 705–707 (2017). https://doi.org/10.1007/s40261-017-0534-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-017-0534-z

Search

Navigation